Skip to main content
. 2017 Oct 30;2017(10):CD006491. doi: 10.1002/14651858.CD006491.pub4

Comparison 1. Mefloquine versus placebo/non users.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Clinical cases of malaria 9 1908 Risk Ratio (M‐H, Random, 95% CI) 0.09 [0.04, 0.19]
2 Malaria; episodes of parasitaemia in semi‐immune populations 5   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
2.1 Trials reporting number of participants with parasitaemia 3 414 Risk Ratio (M‐H, Random, 95% CI) 0.18 [0.06, 0.55]
2.2 Trials reporting number of episodes of parasitaemia 2 510 Risk Ratio (M‐H, Random, 95% CI) 0.05 [0.00, 5.25]
3 Serious adverse events or effects (all studies) 8   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.1 RCTs (adverse events) 6 1221 Risk Ratio (M‐H, Fixed, 95% CI) 0.70 [0.14, 3.53]
3.2 Cohort studies (adverse effects) 2 1167 Risk Ratio (M‐H, Fixed, 95% CI) 3.08 [0.39, 24.11]
4 Discontinuations due to adverse effects (all studies) 7 1130 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [0.55, 4.88]
4.1 RCTs (adverse effects) 7 1130 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [0.55, 4.88]
5 Nausea (all studies) 5   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
5.1 RCTs (adverse events) 2 244 Risk Ratio (M‐H, Fixed, 95% CI) 1.35 [1.05, 1.73]
5.2 Cohort studies (adverse events) 3 1901 Risk Ratio (M‐H, Fixed, 95% CI) 1.85 [1.42, 2.43]
6 Vomiting (all studies) 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
6.1 RCTs (adverse events) 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 0.77 [0.50, 1.19]
6.2 Cohort studies (adverse events) 2 1167 Risk Ratio (M‐H, Fixed, 95% CI) 0.74 [0.45, 1.21]
7 Abdominal pain (all studies) 5   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
7.1 RCTs (adverse events) 3 550 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.84, 1.40]
7.2 Cohort studies (adverse events) 2 1167 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.66, 1.42]
8 Diarrhoea (all studies) 7   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
8.1 RCTs (adverse events) 4 589 Risk Ratio (M‐H, Random, 95% CI) 0.72 [0.32, 1.62]
8.2 Cohort studies (adverse events) 3 1901 Risk Ratio (M‐H, Random, 95% CI) 1.25 [0.93, 1.68]
9 Headache (all studies) 6   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 RCTs (adverse events) 5 791 Risk Ratio (M‐H, Fixed, 95% CI) 0.84 [0.71, 0.99]
9.2 Cohort studies (adverse events) 1 197 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [0.63, 4.26]
10 Dizziness (all studies) 6   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 RCTs (adverse events) 3 452 Risk Ratio (M‐H, Fixed, 95% CI) 1.03 [0.90, 1.17]
10.2 Cohort studies (adverse events) 3 1901 Risk Ratio (M‐H, Fixed, 95% CI) 1.80 [1.29, 2.49]
11 Abnormal dreams (all studies) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
11.1 Cohort studies (adverse events) 2 931 Risk Ratio (M‐H, Fixed, 95% CI) 2.35 [1.15, 4.80]
12 Insomnia (all studies) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 Cohort studies (adverse events) 2 931 Risk Ratio (M‐H, Fixed, 95% CI) 1.46 [1.06, 2.02]
13 Anxiety (all studies) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 Cohort studies (adverse events) 2 931 Risk Ratio (M‐H, Fixed, 95% CI) 1.21 [0.67, 2.21]
14 Depressed mood (all studies) 3   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
14.1 Cohort studies (adverse events) 3 1901 Risk Ratio (M‐H, Random, 95% CI) 2.43 [0.65, 9.07]
15 Abnormal thoughts and perceptions 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 Cohort studies (adverse events) 1 970 Risk Ratio (M‐H, Fixed, 95% CI) 5.77 [0.79, 42.06]
16 Pruritis (all studies) 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 RCTs (adverse events) 3 609 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.60, 1.24]
16.2 Cohort studies (adverse events) 1 197 Risk Ratio (M‐H, Fixed, 95% CI) 6.71 [1.58, 28.55]
17 Visual impairment (all studies) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 RCTs (adverse events) 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 0.98 [0.66, 1.46]
17.2 Cohort studies (adverse events) 1 970 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.27, 3.19]
18 Vertigo (all studies) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
18.1 RCTs (adverse events) 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 1.02 [0.78, 1.34]
19 Other adverse events (RCTs) 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
19.1 Arthralgia 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 0.29 [0.02, 5.48]
19.2 Back pain 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 0.10 [0.01, 1.61]
19.3 Blurred vision 1 208 Risk Ratio (M‐H, Fixed, 95% CI) 0.19 [0.01, 3.89]
19.4 Cough 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 0.90 [0.71, 1.14]
19.5 Constipation 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 0.77 [0.53, 1.11]
19.6 Decreased appetite 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [0.95, 1.28]
19.7 Falls 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 1.08 [0.82, 1.43]
19.8 Fatigue 1 42 Risk Ratio (M‐H, Fixed, 95% CI) 0.91 [0.14, 5.86]
19.9 Gastritis 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 1.02 [0.10, 10.98]
19.10 Myalgia 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 1.53 [0.36, 6.57]
19.11 Rash 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 0.29 [0.04, 2.30]
19.12 Respiratory tract infection 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 2.63 [1.04, 6.61]
19.13 Sore throat 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.04, 2.75]
19.14 Unsteadiness 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.74, 1.52]
19.15 Weakness 1 202 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.96, 1.17]
20 Other adverse effects (cohort studies) 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
20.1 Agitation 1 734 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.61, 1.82]
20.2 Altered spatial perception 1 970 Risk Ratio (M‐H, Fixed, 95% CI) 9.4 [0.57, 153.97]
20.3 Confusion 1 734 Risk Ratio (M‐H, Fixed, 95% CI) 0.67 [0.25, 1.78]
20.4 Loss of appetite 1 970 Risk Ratio (M‐H, Fixed, 95% CI) 0.90 [0.54, 1.50]
20.5 Mouth ulcers 1 970 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.39, 2.56]
20.6 Palpitations 1 197 Risk Ratio (M‐H, Fixed, 95% CI) 8.06 [0.44, 147.68]
20.7 Tingling 1 970 Risk Ratio (M‐H, Fixed, 95% CI) 1.92 [0.59, 6.24]